Vigamox
Vigamox: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Drug interactions
- 10. Analogs
- 11. Terms and conditions of storage
- 12. Terms of dispensing from pharmacies
- 13. Reviews
- 14. Price in pharmacies
Latin name: Vigamox
ATX code: S01AE07
Active ingredient: Moxifloxacin (Moxifloxacin)
Producer: Alkon Pharmaceuticals, Russia
Description and photo update: 2019-13-08
Prices in pharmacies: from 150 rubles.
Buy
Vigamox is a local antibacterial drug used in the treatment of bacterial conjunctivitis.
Release form and composition
Vigamox is produced in the form of 0.5% eye drops, in plastic dropper bottles of 3 ml and 5 ml, 1 bottle in a cardboard box.
The composition of 1 ml of drops contains 5 μg of the active substance - moxifloxacin.
Pharmacological properties
Pharmacodynamics
Moxifloxacin - the active component of Vigamox - is a IV generation fluoroquinolone antibacterial drug and is characterized by a bactericidal effect. It is active against a wide range of gram-negative and gram-positive microorganisms, atypical, acid-fast and anaerobic bacteria.
This compound inhibits topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an enzyme involved in the repair, transcription, and replication of bacterial DNA. Topoisomerase IV is an enzyme involved in the cleavage of chromosomal DNA during bacterial cell division.
Vigamox is not cross-resistant to tetracyclines, aminoglycosides and macrolides. There are isolated reports of cross-resistance between moxifloxacin used systemically and other fluoroquinolones.
Moxifloxacin is active against most of the following microbial strains (both in vivo and in vitro):
- gram-negative bacteria: Klebsiella spp., Acinetobacter lwojfii, Haemophilus parainfluenzae, Haemophilus influenzae (including strains that are not sensitive to ampicillin);
- gram-positive bacteria: Streptococcus viridians (including strains insensitive to trimethoprim and / or tetracycline, erythromycin, penicillin), Streptococcus pneumoniae (including strains insensitive to trimethoprim and / or tetracycline, penicillin, erythromycin, penicillin), Streptococcus pneumoniae (including strains insensitive to trimethoprim and / or tetracycline, penicillin, erythromycin, gentamicillin) (including strains insensitive to trimethoprim and / or tetracycline, erythromycin, penicillin), Corynebacterium spp., including Corynebacterium diphtheriae, Staphylococcus warneri (including strains insensitive to erythromycin), Sturetamushylococcus, including trimethoprim and / or tetracycline, methicillin, ofloxacin, gentamicin, erythromycin), Staphylococcus hominis (including strains insensitive to trimethoprim and / or tetracycline, methicillin, ofloxacin, gentamicin, erythromycin),Staphylococcus haemolyticus (including strains insensitive to trimethoprim and / or tetracycline, methicillin, ofloxacin, erythromycin, gentamicin), Staphylococcus epidermidis (including strains insensitive to trimethoprim and / or tetracycline, erythromycin, erythromycin) Micrococcus luteus (including strains insensitive to trimethoprim and / or tetracycline, gentamicin, erythromycin);
- other microorganisms: Chlamydia
The effect of moxifloxacin in vitro on the following microorganisms has been revealed (however, the clinical significance of this phenomenon has not been sufficiently studied):
- gram-negative bacteria: Pseudomonas stutzeri, Acinetobacter calcoaceticus, Acinetobacter baumannii, Proteus vulgaris, Proteus mirabilis, Citrobacter koseri, Citrobacter freundii, Neisseria gonorrhoeae, Enterobacter cloacae, Enterobacter morcaichiae, Enterobacter aerogenes, Morganella olella
- gram-positive bacteria: Streptococcus groups F, G, C, Streptococcus pyogenes, Streptococcus mitis, Streptococcus agalactiae, Staphylococcus saprophyticus, Listeria monocytogenes;
- anaerobic microorganisms: Propionibacterium acnes, Clostridium perfringens, Prevotella spp., Fusobacterium spp.;
- other microorganisms: Mycoplasma pneumoniae, Chlamydia pneumoniae, Mycobacterium marinum, Mycobacterium avium, Legionella pneumophila.
Pharmacokinetics
With local application of Vigamox, systemic absorption of moxifloxacin is observed. The maximum plasma concentration of the substance is 2.7 ng / ml, and the AUC indicator reaches 45 ng * h / ml. These values are approximately 1600 and 1000 times less than the corresponding values for oral administration of moxifloxacin at a therapeutic dose of 400 mg. The half-life of the compound from blood plasma is approximately 13 hours.
Indications for use
Vigamox eye drops are prescribed for the treatment of bacterial conjunctivitis caused by microorganisms sensitive to the action of the active substance (moxifloxacin).
Contraindications
- Lactation period (breastfeeding);
- Children under 1 year old;
- Hypersensitivity to the components of the drug or to other quinolones.
According to the instructions, Vigamox during pregnancy (FDA category C) can be used only in cases where the expected therapeutic effect for the mother outweighs the possible risk for the child.
Instructions for use of Vigamox: method and dosage
Vigamox is intended for topical use.
Children from 1 year old and adults are instilled 3 times a day, 1 drop into the affected eye. As a rule, improvement of the condition occurs after 5 days. Therapy should be continued for another 2-3 days. If after 5 days the condition does not improve, it is necessary to clarify the diagnosis and the correctness of the treatment.
The duration of Vigamox use is determined by the severity of the condition, as well as the bacteriological and clinical course of the disease.
Side effects
When using Vigamox, the following may develop:
- Systemic reactions. Most often (in 1-10% of patients) dysgeusia occurs. Rarely (in 0.1-1% of patients) there were: paresthesia, headache, decreased blood hemoglobin, pharyngolaryngeal pain, discomfort in the nose, sensation of a foreign body in the throat, increased levels of alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT), vomiting;
- Local reactions. In most cases (in 1-10% of patients), they manifest themselves as dry eye syndrome, pain, itching and irritation in the eye, redness of the eye and conjunctiva. Sometimes (0.1-1% of patients) develop: punctate keratitis, corneal epithelial defect, conjunctivitis, subconjunctival hemorrhage, eye edema, unusual sensations in the eye, blurred vision, a feeling of discomfort in the eyes, erythema of the eyelids, decreased visual acuity.
As a result of post-marketing studies, it was found that Vigamox can lead to the development of such side effects (frequency is unknown):
- Systemic reactions: itching of the skin, dizziness, palpitations, nausea, shortness of breath, rash, erythema, hypersensitivity;
- Local reactions: formation of corneal defects, ulcerative keratitis, eye discharge, endophthalmitis, corneal erosion, increased intraocular pressure, corneal opacity and infiltrates, allergic reactions of the eye, corneal deposits, corneal edema, keratitis, increased tearing, photophobia, edema, eyelids, bleeding feeling of a foreign body in the eye.
If allergic reactions occur, the drug should be canceled.
Overdose
If an excessive amount of Vigamox gets into your eyes, you must immediately rinse them with warm water.
special instructions
Long-term use of the antibiotic can lead to an overgrowth of resistant microorganisms, including fungi. With the development of superinfection, Vigamox should be canceled, after which adequate therapy should be prescribed.
The bottle must be closed after each use.
Do not touch the tip of the dropper bottle with the drug to any surface, this will help to avoid contamination of the bottle and its contents.
After using Vigamox eye drops, a temporary decrease in the clarity of visual perception is possible, and it is not recommended to drive a car and engage in activities that require an increased response and attention from the patient until it is restored.
Drug interactions
There is no information on interactions with other medicinal products.
Analogs
Analogs of Vigamox are: Moxifur, Moflox, Moxifloxacin, Avelox, Tevalox, Floxal.
Terms and conditions of storage
Store in a dark, dry place out of the reach of children at a temperature of 2-25 ° C.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Vigamox
The drug is often used for barley and conjunctivitis, especially in pediatric patients. According to reviews, Vigamox is very effective in these cases and acts quickly enough. However, some patients do not like the large number of adverse reactions, including allergic ones, and the high cost of the drug: they prefer more affordable analogues.
Price for Vigamox in pharmacies
The approximate price of Vigamox in pharmacy chains is 219–258 rubles (for a 5 ml bottle).
Vigamox: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Vigamox 0.5% eye drops 5 ml 1 pc. RUB 150 Buy |
|
Vigamox eye drops 0.5% 5ml 191 r Buy |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
